000147246 001__ 147246
000147246 005__ 20260112133314.0
000147246 0247_ $$2doi$$a10.3390/ph17111438
000147246 0248_ $$2sideral$$a141074
000147246 037__ $$aART-2024-141074
000147246 041__ $$aeng
000147246 100__ $$aCásedas, Guillermo
000147246 245__ $$aCannabidiol (CBD): A Systematic Review of Clinical and Preclinical Evidence in the Treatment of Pain
000147246 260__ $$c2024
000147246 5060_ $$aAccess copy available to the general public$$fUnrestricted
000147246 5203_ $$aBackground/Objectives: Cannabis sativa L. is a plant that has been used for thousands of years for its industrial and medicinal properties. In recent years, there has been a rise in the study of this plant due to its bioactive compounds for pharmaceutical applications. Particularly, cannabidiol has demonstrated analgesic and non-psychoactive properties. The objective of this systematic review is to update and to gather the clinical and preclinical evidence on CBD in pain treatment. Methods: This study was performed following the PRISMA guidelines and using the following search terms “((cannabidiol) NOT (THC)) NOT (tetrahydrocannabinol)) AND (pain treatment)” in PubMed and Web of Science, with the following inclusion criteria: CBD pain treatment without THC in monotherapy, including both clinical and preclinical trials. From the initial sample of more than 500 articles, a total of 40 studies were selected, eliminating duplicate studies from the databases and considering the inclusion and exclusion criteria. On one hand, clinical trials were analyzed using CBD products without THC used in monotherapy, assigning a Jadad score to evaluate the quality/bias of the trials; on the other hand, the main preclinical trials were analyzed, grouping the results into in vivo and in vitro trials. Results: Based on the review conducted, there is sufficient clinical and preclinical evidence of CBD in pain treatment, so CBD could be an effective and safe treatment in reducing pain due to its analgesic and anti-inflammatory properties. These effects appear to be primarily mediated by the activation of TRPV-1, 5HT-1A, and CB1, with emerging therapeutic relevance in the management of osteoarthritis and chronic pain. Conclusions: Although clinical and preclinical research show promising results, clinical evidence is limited, and more studies should be performed in the future with isolated CBD.
000147246 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000147246 590__ $$a4.8$$b2024
000147246 592__ $$a1.019$$b2024
000147246 591__ $$aPHARMACOLOGY & PHARMACY$$b51 / 352 = 0.145$$c2024$$dQ1$$eT1
000147246 593__ $$aDrug Discovery$$c2024$$dQ1
000147246 591__ $$aCHEMISTRY, MEDICINAL$$b18 / 72 = 0.25$$c2024$$dQ1$$eT1
000147246 593__ $$aPharmaceutical Science$$c2024$$dQ1
000147246 593__ $$aMolecular Medicine$$c2024$$dQ2
000147246 594__ $$a7.7$$b2024
000147246 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion
000147246 700__ $$aYarza-Sancho, Martín de
000147246 700__ $$aLópez, Víctor
000147246 773__ $$g17, 11 (2024), 1438 [14 pp.]$$pPharmaceuticals$$tPharmaceuticals$$x1424-8247
000147246 8564_ $$s1173318$$uhttps://zaguan.unizar.es/record/147246/files/texto_completo.pdf$$yVersión publicada
000147246 8564_ $$s2692531$$uhttps://zaguan.unizar.es/record/147246/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000147246 909CO $$ooai:zaguan.unizar.es:147246$$particulos$$pdriver
000147246 951__ $$a2026-01-12-13:03:37
000147246 980__ $$aARTICLE